PTC Therapeutics, Inc.
PTCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | -0.44 | -1.01 | -0.45 |
| FCF Yield | -3.29% | -13.53% | -18.60% | -12.00% |
| EV / EBITDA | -42.84 | -11.19 | -10.66 | -10.56 |
| Quality | ||||
| ROIC | -21.70% | -20.93% | -30.25% | -20.72% |
| Gross Margin | 92.89% | 69.28% | 93.61% | 94.00% |
| Cash Conversion Ratio | 0.30 | 0.25 | 0.64 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.91% | 20.31% | 22.43% | 20.61% |
| Free Cash Flow Growth | 59.08% | 45.19% | -51.22% | -34.64% |
| Safety | ||||
| Net Debt / EBITDA | -14.04 | -4.95 | -3.21 | -2.93 |
| Interest Coverage | -1.81 | -2.70 | -4.84 | -4.36 |
| Efficiency | ||||
| Inventory Turnover | 2.47 | 9.42 | 2.05 | 2.04 |
| Cash Conversion Cycle | 109.38 | 93.75 | 36.67 | -6.18 |